- Home
- INO vs NVNO Comparison
INO vs NVNO Comparison
Compare INO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- NVNO
- Stock Information
- Founded
- INO 1979
- NVNO 1987
- Country
- INO United States
- NVNO United States
- Employees
- INO N/A
- NVNO N/A
- Industry
- INO Medical/Dental Instruments
- NVNO Medical/Dental Instruments
- Sector
- INO Health Care
- NVNO Health Care
- Exchange
- INO Nasdaq
- NVNO Nasdaq
- Market Cap
- INO 69.3M
- NVNO 71.0M
- IPO Year
- INO 1998
- NVNO N/A
- Fundamental
- Price
- INO $1.43
- NVNO $4.89
- Analyst Decision
- INO Buy
- NVNO
- Analyst Count
- INO 5
- NVNO 0
- Target Price
- INO $8.80
- NVNO N/A
- AVG Volume (30 Days)
- INO 3.4M
- NVNO 138.1K
- Earning Date
- INO 08-07-2025
- NVNO 08-08-2025
- Dividend Yield
- INO N/A
- NVNO N/A
- EPS Growth
- INO N/A
- NVNO N/A
- EPS
- INO N/A
- NVNO N/A
- Revenue
- INO $283,099.00
- NVNO N/A
- Revenue This Year
- INO N/A
- NVNO N/A
- Revenue Next Year
- INO $20,588.06
- NVNO N/A
- P/E Ratio
- INO N/A
- NVNO N/A
- Revenue Growth
- INO N/A
- NVNO N/A
- 52 Week Low
- INO $1.30
- NVNO $2.03
- 52 Week High
- INO $11.44
- NVNO $5.92
- Technical
- Relative Strength Index (RSI)
- INO 40.29
- NVNO 58.30
- Support Level
- INO $1.46
- NVNO $4.65
- Resistance Level
- INO $1.56
- NVNO $5.27
- Average True Range (ATR)
- INO 0.08
- NVNO 0.40
- MACD
- INO 0.02
- NVNO 0.03
- Stochastic Oscillator
- INO 43.33
- NVNO 51.66
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.